Clinical Evaluation of Flortaucipir F 18

Exclusion Criteria

• •Have clinically significant cardiac, hepatic, renal, pulmonary, metabolic, or endocrine disturbances
• •Have a screening electrocardiogram with a corrected QT interval (QTc) \> 450 msec if male or QTc \> 470 msec if female
• •Have a history of additional risk factors for Torsades de Pointes (TdP) or are taking drugs known to cause QT-prolongation. Patients with a prolonged QTc interval in the setting of intraventricular conduction block may be enrolled with sponsor approval
• •Have a history of drug or alcohol dependence within the last year, or prior prolonged history of dependence unless approved by the sponsor
• •Are females of childbearing potential who are not surgically sterile, not refraining from sexual activity or not using reliable methods of contraception
• •Have a history of relevant severe drug allergy or hypersensitivity
• •Are patients who have received an investigational medication within 30 days prior to the planned imaging session for this study
• •Are patients with current clinically significant unstable medical comorbidities
• •Are patients who have received a radiopharmaceutical for imaging or therapy within the past 24 hours prior to the imaging session for this study